CHS 2017 Annual Report
The year 2017 was a remarkable one. Together, we have made noteworthy advancements
towards our vision for the inherited bleeding disorder community.
Hemophilia Today
Check out the latest issue of the CHS’ newsmagazine, Hemophilia Today, for information, current news and issues relevant to the bleeding disorder community.
MyCBDR
MyCBDR is the system used by patients and/or their caregivers who are on home treatment. It is linked directly to the CBDR at your treatment centre.
Research and market studies
Please take the time to see what is presently happening with regards to research and market studies and to see if you could take an active part in them.
STRATEGIC PLAN | 2016‐2020
Deaths of patients receiving emicizumab judged unrelated to drug
MONTREAL – March 29, 2018 – On March 29, 2018, following considerable social media activity, Roche released a statement on the deaths of five patients who had been receiving emicizumab.
Q&A about RFPs
We often receive questions about the tender process (RFP) for clotting factor concentrates. We produced a Q&A document which we hope will answer all your questions on the topic.
Recombinant factor concentrate charts
Please check out our updated charts listing the recombinant factor concentrates and their description.
REACH US AT
1-800-668-2686
chs@hemophilia.ca
WE’RE HERE TO HELP.
